Ur24Technology Launches New and Unique ‘TrueClr’ External Catheter Line
11.11.2022 10:00:00 EET | Business Wire | Press release
Ur24Technology Inc., a privately held medical device company, has launched the TrueClr catheter product line – offering physicians, nurses and patients a choice that will eliminate catheter-associated urinary tract infections in hospitals, increase patient comfort and quality of life, and lower health care costs.
The first external catheter designed to actively empty the bladder, the new latex-free TrueClr product line for adults and children will be showcased at Medica 2022, one of the world’s leading medical trade fairs, in Dusseldorf, Germany from Nov. 13-17.
Dr. Jon Meliones, M.D., FCCM, medical director at Ur24Technology, said: “I am convinced the TrueClr external catheters will fundamentally revolutionize medical practices. It’s an active elimination system vs. passive - the only catheter of its kind in the world.” Dr. Meliones will be a featured speaker at Medica 2022.
US data shows that internal catheters are associated with 80 percent of hospital-related urinary tract infections, which cost the health care system an estimated $450 million yearly. Nearly 13,000 deaths annually are related to internal catheters. Key features of the TrueClr product line include:
- Eliminates internal catheter-associated urinary tract infections
- Uses light, continuous section
- Non-invasive, non-adhesive, comfortable
- Leak proof design
- Avoids urine contact with skin
- Eliminates skin irritation and inflammation
- Portable & reusable – in hospitals or at home, with easy cleaning
- Covered under Medicare Part B, DME reimbursement
Ur24 Technology has a strategic partnership with Miami-based DemeTECH Corp. to manufacture and distribute TrueClr products in the US and internationally, using its distribution network in 132 countries. The companies will jointly promote TrueClr, which will be co-branded, at Medica 2022.
About Ur24Technology, Inc.
Ur24Technology, Inc. is a privately held medical device company located in Southern California that was founded in 2016 by Landon Duval. Five different external catheter prototypes were researched, designed and developed – leading to the TrueClr external catheter range of products. These revolutionary products perfectly fit the company’s core mission: to improve patient care through innovation.
Learn more at www.ur24technology.com or call 1-833-448-7248.
About DemeTECH Corp.
Headquartered in Miami, Florida, DemeTECH, is a world-renowned leader in surgical sutures, mesh and bone wax. DemeTECH strives to enhance doctor-patient relationships through hard work, dedication, and a commitment to the pursuance of cutting-edge technology and innovation. DemeTECH’s N95 masks and TrueClr external catheters are made in the USA with American materials.
Learn more at https://demetech.us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005156/en/
Contact information
Victoria Suarez
Chief Operating Officer
949.629.5424
info@ur24technology.com
www.ur24technology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 08:07:00 EET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 202628.1.2026 08:00:00 EET | Press release
The NTT Group, comprising NTT, Inc., NTT DOCOMO, INC., and NTT DATA Group Corporation, announced today that they will jointly exhibit at MWC Barcelona 2026, the world’s largest connectivity event, to be held in Barcelona, Spain, from March 2 to March 5, 2026. At this event, the NTT Group will showcase its technological capabilities and foster deeper connections with leading global companies. Under the unified concept introduced following the corporate identity (CI) renewal on July 1, 2025, the NTT Group aims to strengthen its global brand presence and expand its business internationally. This will be the NTT Group’s first joint exhibition in seven years since 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127239513/en/ The NTT Group Booth at MWC Barcelona 2026 Under the theme, “Photonics Unlocks an Intelligent Power-Optimized Future,” the NTT Group will present its initiatives centered around IOWN1 optical technolog
Multi-Color Corporation Announces Recapitalization to Reset Balance Sheet and Position Company for Long-Term Growth and Investment27.1.2026 23:09:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced strategic actions to further position the Company for long-term growth and investment to best serve its customers. MCC has entered into a restructuring support agreement (the “RSA”) with holders of approximately 70% in amount of MCC’s secured first lien debt and its equity sponsor, CD&R, on the terms of a comprehensive financial restructuring. The transactions contemplated by the RSA will significantly deleverage MCC’s balance sheet, reducing its net debt load from approximately $5.9 billion to approximately $2.0 billion. The Company’s annualized cash interest will also be reduced from approximately $475 million to $140 million in 2026, a reduction of over $330 million, with long-term debt maturities extended to 2033 following consummation of the restructuring transactions. To implement the transactions contemplated by the RSA, MCC has launched a solicitation for votes in support
Logitech Announces Q3 Fiscal Year 2026 Results27.1.2026 23:05:00 EET | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2026. Sales were $1.42 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q3 of the prior year. GAAP gross margin was 43.2 percent, up 30 basis points compared to Q3 of the prior year. Non-GAAP gross margin was 43.5 percent, up 30 basis points compared to Q3 of the prior year. GAAP operating income was $286 million, up 22 percent compared to Q3 of the prior year. Non-GAAP operating income was $312 million, up 17 percent compared to Q3 of the prior year. GAAP earnings per share (EPS) was $1.69, up 28 percent compared to Q3 of the prior year. Non-GAAP EPS was $1.93, up 21 percent compared to Q3 of the prior year. Cash flow from operations was $481 million. The quarter-ending cash balance was $1.8 billion. “We delivered another quarter of excellent financial performance,” sai
Mobileum Launches GlobalRoamer® Connectivity Package for the FIFA World Cup 2026 to Assure Seamless Roaming and 5G Voice Performance Across North America27.1.2026 22:45:00 EET | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced a Special GlobalRoamer® package for the FIFA World Cup 2026, designed to help mobile network operators (MNOs) validate roaming readiness and maintain high-quality connectivity during one of the world’s most demanding network events, where service performance directly impacts roaming revenue, customer retention, and brand reputation. The FIFA World Cup 2026 will place unprecedented pressure on mobile networks across 16 stadiums in the United States, Canada, and Mexico, as millions of fans, teams, media, and officials rely on mobile services to stream, share, and communicate in real time. Sudden spikes in data, voice, and roaming traffic can degrade performance precisely when customer experience is most visible. Mobileum’s FIFA World Cup 2026 package builds on the GlobalRoamer® end-to-end active testing ecosystem used at major global events, including roaming quality campaigns conduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom